With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million
The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, compared with $753.9 million at the end of 2025, while maintaining expectations that its cash runway will extend into early 2028. CEO Najat Khan stated that the company continues seeing strong execution across its portfolio, including encouraging initial safety and pharmacokinetic data from REC-1245 and the first patient dosing in REC-4539. Management emphasized that the progress demonstrates the company’s ability to translate biological and chemical insights generated by its AI-driven platform into differentiated clinical-stage programs.
Earlier, on April 30, JPMorgan Chase & Co. lowered its price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $10 from $11 while maintaining an Overweight rating on the shares. The firm’s continued positive stance reflects confidence in the company’s long-term AI-enabled drug discovery platform despite near-term financial pressures and ongoing clinical development costs. Recursion Pharmaceuticals is a clinical-stage TechBio company that integrates artificial intelligence, machine learning, and automation to industrialize drug discovery and development.